Compounds > sb-681323
Page last updated: 2024-11-12

sb-681323

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10297982
CHEMBL ID2103838
SCHEMBL ID1065268
MeSH IDM0576146

Synonyms (47)

Synonym
D09602
444606-18-2
dilmapimod (usan/inn)
dilmapimod ,
8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-((2-hydroxy-1- (hydroxymethyl)ethyl)amino)pyrido(2,3-d)pyrimidin-7(8h)-one
dilmapimod [usan:inn]
pyrido(2,3-d)pyrimidin-7(8h)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2- ((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-
gsk 681323
sb-681323
q3238vqw0n ,
unii-q3238vqw0n
sb 681323
gw 681323
gw-681323
CHEMBL2103838
sb681323
8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}pyrido[2,3-d]pyrimidin-7(8h)-one
pyrido(2,3-d)pyrimidin-7(8h)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-
dilmapimod [inn]
dilmapimod [usan]
gtpl7815
8-(2,6-difluorophenyl)-2-(1,3-dihydroxypropan-2-ylamino)-4-(4-fluoro-2-methylphenyl)pyrido[6,5-d]pyrimidin-7-one
SCHEMBL1065268
8-(2,6-difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8h-pyrido[2,3-d]pyrimidin-7-one
ORVNHOYNEHYKJG-UHFFFAOYSA-N
8-(2,6-difluorophenyl)-2-((1,3-dihydroxypropan-2-yl)amino)-4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7(8h)-one
gw681323
8-(2,6-difluorophenyl)-2-(1,3-dihydroxypropan-2-ylamino)-4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7-one
CS-6731
HY-10404
sb-681323; gw-681323
DB12140
EX-A3567
FT-0718750
BCP23819
sb 681323; sb681323; gw 681323; gw-681323; gw681323; dilmapimod
444606-18-2 (free base)
Q27077064
SB16737
sb-681323; gw 681323
D80612
dilmapimod (sb-681323)
MS-28316
gw 681323;sb-681323;dilmapimod;8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-pyrido[2,3-d]pyrimidin-7(8h)-one
A900306
DTXSID101318338
AKOS040737590

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Although adverse events were common in this critically ill population, dilmapimod was well tolerated, with no clinically relevant safety findings."( A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.
Bayliffe, AI; Chang, PK; Christie, JD; Gunn, SR; Hardes, K; Kahl, L; Lazaar, AL; Lipson, DA; May, AK; Powley, WM; Vaslef, S; Yang, S, 2015)		0.42

Pharmacokinetics

ExcerptReferenceRelevance
" The purpose of this paper is to present the details of the development of a population pharmacokinetic (PK) model, an empirical population placebo response model, and the exploration of a PK/pharmacodynamic (PD) model of dilmapimod."( Population Pharmacokinetics and Pharmacodynamics Modelling of Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.
Dumitrescu, TP; Yang, S, 2017)		0.46

Dosage Studied

ExcerptRelevanceReference
" Likewise, measures of soluble inflammatory markers including interleukin-6, C-reactive peptide, interleukin-8, and soluble tumor necrosis factor receptor 1 were most different between this dosing arm and placebo."( A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.
Bayliffe, AI; Chang, PK; Christie, JD; Gunn, SR; Hardes, K; Kahl, L; Lazaar, AL; Lipson, DA; May, AK; Powley, WM; Vaslef, S; Yang, S, 2015)		0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.99 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (66.67%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other1 (16.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		4.361111beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
citrulline
citrulline : The parent compound of the citrulline class consisting of ornithine having a carbamoyl group at the N(5)-position.		2.2510amino acid zwitterion;
citrulline		Daphnia magna metabolite;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
protective agent;
Saccharomyces cerevisiae metabolite
rosiglitazone
[no description available]		3.2310aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		4.4111
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		2.2510ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		3.2310
pepbs1-ac peptide
AP301 peptide: a synthetic peptide mimicking the lectin-like domain of TNF		2.2510
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Respiratory Distress Syndrome
[description not available]		05.7132
Respiratory Distress Syndrome
A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.		05.7132
Injuries
Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.		05.422
Wounds and Injuries
Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.		05.422
Pain, Chronic
[description not available]		03.0410
Nerve Pain
[description not available]		04.821
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		16.821
Chronic Pain
Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.		03.0410
Airflow Obstruction, Chronic
[description not available]		04.3611
Innate Inflammatory Response
[description not available]		04.3611
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		09.3611
Pulmonary Disease, Chronic Obstructive
A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.		16.3611